ABLYNX ANNOUNCES WARRANT EXERCISE
December 16, 2015 12:13 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
ABLYNX ANNOUNCES WARRANT EXERCISE
December 09, 2015 01:07 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX
December 02, 2015 01:04 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC:...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
December 01, 2015 01:05 ET
|
Ablynx
REGULATED...
ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER
November 30, 2015 01:14 ET
|
Ablynx
Clinical Immunologist with more than 15 years combined FDA and pharmaceutical industry experience
Successfully developed a broad range of drugs in a number of important therapeutic...
ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK
November 25, 2015 01:06 ET
|
Ablynx
Ablynx to receive a €5 million upfront payment, research funding, potential future milestones and royalties on net sale
New pharmaceutical partner for Ablynx bringing disease...
ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015
November 18, 2015 01:08 ET
|
Ablynx
REGULATED INFORMATION
Clinical pipeline further advanced with one Phase III and four Phase II studies currently on-going in-house, and first potential product launch in 2018
Significant...
ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY
November 05, 2015 01:05 ET
|
Ablynx
Bi-specific Nanobody demonstrates superior efficacy as compared to reference monoclonal antibody drugs
Bi-specific Nanobody strongly inhibits proliferation and survival of human endothelial...
ABLYNX ANNOUNCES WARRANT EXERCISE
October 21, 2015 01:08 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
October 15, 2015 01:09 ET
|
Ablynx
Bi-specific Nanobody construct achieves pre-clinical proof-of-concept in tumour model
Ablynx to receive €3.5 million milestone payment
GHENT/ZWIJNAARDE, Belgium,...